OncoMatch/Clinical Trials/NCT07318675
A Phase Ib Study of HW211026 Ointment in Patients With Actinic Keratosis.
Is NCT07318675 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies HW211026 for actinic keratosis (ak).
Treatment: HW211026 — This is a phase Ib study to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) characteristics of HW211026 ointment after single or multiple topical administrations in patients with actinic keratosis.
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage OLSEN GRADE 1, OLSEN GRADE 2 (Olsen)
Olsen grade 1 or 2
Prior therapy
Cannot have received: systemic drug therapy for actinic keratosis
Cannot have received: topical intervention for actinic keratosis
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify